Oncolytics reports 3-4x longer response duration in second-line RAS-mutant colorectal cancer patients

Oncolytics Biotech announced that its investigational immunotherapy pelareorep showed a median response duration of 19.5 months in second-line RAS-mutant, microsatellite-stable metastatic colorectal cancer patients, significantly exceeding the historical 4-6 month benchmark. The combination therapy also achieved a 33% objective response rate, tripling standard care outcomes. The company is engaging with the FDA to pursue accelerated approval based on these promising results and is currently enrolling patients in a Phase 2 trial. This development addresses a critical unmet need in a difficult-to-treat cancer population, potentially offering a new effective treatment option.